A procurement-literacy guide to UAE medical-product rules that laboratories should read before ordering research peptides — Federal Decree-Law 38 of 2024, EDE services, and why a research-use label is not a marketing authorisation.
The question people actually type
Searches such as “are peptides legal in the UAE” or “are peptides legal in Dubai” want a one-word answer. Official pages do not publish a peptide-wide whitelist or blacklist. Classification depends on the compound, the presentation, the intended use, and who is handling it.
This page is for UAE laboratories and procurement teams who need a readable map of the public framework — not a slogan, and not legal advice. UAEPEP supplies laboratory research materials only. Nothing here authorises human or veterinary use.
What the official texts actually cover
Federal Decree-Law No. (38) of 2024 governing medical products, pharmacists and pharmaceutical establishments is published on the UAE Legislation portal. It is the current federal medical-product framework. How any specific peptide SKU sits inside that framework is a facts-and-licence question — not a marketing-label question.
The Ministry of Health and Prevention (MOHAP) announced that selected services moved to the Emirates Drug Establishment (EDE). The transferred list includes non-clinical and clinical research entities, R&D contracting companies, marketing authorisations for medical products, and approvals or permits to import, export, or re-export medical products. Requests for those listed services go through the EDE portal.
| Source | What it is | What it is not |
|---|---|---|
| Federal Decree-Law No. (38) of 2024 | Federal medical-product / pharmacy / establishment framework | A published list of every research peptide |
| MOHAP → EDE service transfer | Who receives selected research-entity and import/export requests | A statement that every RUO vial is cleared |
| UAEPEP catalogue language | Intended-use statement for laboratory procurement | A licence, permit, or marketing authorisation |
Research-use labelling versus a medicine pathway
A compounding pharmacy that dispenses a peptide under a physician prescription is on a clinical / pharmaceutical track. A research catalogue that sells lyophilised laboratory materials with research-only language is stating a different intended use.
Those tracks must not be mixed on paperwork. If your institution needs a prescription medicine or a compounded preparation, that is not what uaepep.ae sells. If your laboratory needs a documented research SKU with a batch COA, that is the UAEPEP job.
- UAEPEP does not diagnose, treat, dose, or prescribe
- Checkout requires a research-use acknowledgement
- Public COAs are lot-linked research documents — not clinical licences
- Institutional buyers should confirm their own EDE / ethics / import pathway when it applies
What UAEPEP will and will not claim
We will not tell you that an RUO sticker makes every peptide lawful for every buyer. We will not publish city doorway pages that pretend Abu Dhabi and Dubai are different legal products. We will not write dosing, cycles, or weight-loss claims on research SKUs.
We will keep the trading entity visible (UAEPEP FOR LABORATORIES CHEMICALS TRADING LLC, Dubai Science Park), keep strengths in mg / mcg / ml, keep batch COAs on the product path, and keep delivery and payment in plain language.
Practical next step for a laboratory buyer
If you are buying for a documented research workflow, open the catalogue, match the SKU and strength, read the COA, and complete checkout with the research acknowledgement. If you need a clinical or compounded product, stop — that is a different regulated channel.
Questions about catalogue documentation: info@uaepep.ae. Order timing: support@uaepep.ae. Institutional purchasing: business@uaepep.ae.
Frequently asked questions
Next step
Read the research-use terms
Not legal advice · Laboratory intended use